UNITED THERAPEUTICS (UTH BE) stock market data APIs
€363.1746
4.42(1.2%)
as of October 24, 2025
Try our APIs with
free plan!
UNITED THERAPEUTICS Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for UTH.BE.
Prev. Close
363.1746
Open
367.5914
High
372.3587
Low
360.4914
52 wk Range
237.2-394.3
Market Cap
7 520 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get UNITED THERAPEUTICS data using free add-ons & libraries
Get UNITED THERAPEUTICS Fundamental Data
UNITED THERAPEUTICS Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: 7.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
UNITED THERAPEUTICS News
New
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
United Therapeutics (UTHR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus out...
Why The Narrative Around United Therapeutics Is Shifting After Major Clinical and Pipeline Updates
United Therapeutics recently saw its fair value price target rise slightly from $484.77 to $492.85, reflecting a modest increase in expected intrinsic value. This adjustment comes alongside a marginal...
Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case
United Therapeutics Corporation (NASDAQ:UTHR) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 2, Jefferies reiterated its “Buy” rating and a price ...
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., October 15, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financia...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
